Field, K and Wong, H-L and Shapiro, J and Kosmider, S and Tie, J and Bae, S and Yip, D and Mckendrick, J and Nott, L and Desai, J and Harold, M and Lipton, L and Stefanou, G and Lim, L and Parente, P and Gibbs, P, Developing a national database for metastatic colorectal cancer management: Perspectives and challenges, Internal Medicine Journal, 43, (11) pp. 1224-1231. ISSN 1444-0903 (2013) [Refereed Article]
Copyright 2013 Royal Australasian College of Physicians
Background: The changing treatment landscape for metastatic colorectal cancer creates multiple potential treatment strategies. An Australian-centric database capturing comprehensive information across a range of treatment locations would create a valuable resource enabling multiple important research questions to be addressed.
Aims: To establish a collection of a consensus dataset capturing treatment and outcomes at multiple public and private hospitals across Australia.
Methods: An electronic database was developed by a panel of clinicians, to capture an agreed dataset for patients with newly diagnosed metastatic colorectal cancer. Of particular interest were clinician decision-making, the impact of comorbidities and the frequency of major adverse events.
Results: Since July 2009, data collection has been established at six public and eight private hospitals across three Australian states and territories. Successful linkage and analysis, with support from BioGrid Australia, of selected data on the initial 864 patients demonstrates that data can be captured from diverse sites, including public and private practice, that multiple factors impact on treatment delivered and outcomes achieved and that comprehensive data on rare but important adverse events can be captured. As a clinical research tool, the project has been highly successful, generating multiple presentations at national and international conferences related to a diverse range of research questions.
Conclusions: Multistate, project-specific data collection involving large numbers of patients is achievable. Providing invaluable insight into the routine clinical management of metastatic colorectal cancer in the era of targeted therapies, this also creates a significant resource for research, including many questions not being addressed by clinical trials.
|Item Type:||Refereed Article|
|Keywords:||adverse event, bevacizumab, data collection, metastatic colorectal cancer, survival, B Raf kinase, bevacizumab, capecitabine, carcinoembryonic antigen, fluorouracil, folinic acid, irinotecan, K ras protein, oxaliplatin, adult, adverse outcome, aged|
|Research Division:||Biomedical and Clinical Sciences|
|Research Group:||Oncology and carcinogenesis|
|Research Field:||Cancer therapy (excl. chemotherapy and radiation therapy)|
|Objective Group:||Clinical health|
|Objective Field:||Clinical health not elsewhere classified|
|UTAS Author:||Nott, L (Dr Louise Nott)|
|Web of Science® Times Cited:||32|
|Deposited By:||Menzies Institute for Medical Research|
Repository Staff Only: item control page